Flavone Acetic Acid and Interleukin-2 in Melanoma Treatment
Author Information
Author(s): L.L. Thomsen, B.C. Baguley, G.J.S. Rustin, S.M. O'Reilly
Primary Institution: Cancer Research Laboratory, University of Auckland School of Medicine
Hypothesis
Does the combination of Flavone Acetic Acid (FAA) and recombinant interleukin-2 (rhIL-2) induce nitric oxide production in patients with metastatic melanoma?
Conclusion
The study found that treatment with FAA and rhIL-2 significantly increased plasma nitrate levels, indicating enhanced nitric oxide production.
Supporting Evidence
- Plasma nitrate levels before treatment were significantly higher in cancer patients than in healthy volunteers.
- Three patients showed a clinical response to treatment, with higher plasma nitrate concentrations.
- Most increases in plasma nitrate occurred 3-5 days after starting rhIL-2 infusion.
Takeaway
Doctors tested a new treatment for skin cancer that combines two medicines, and they found that it helps the body make a special chemical that can fight cancer.
Methodology
Plasma samples were collected from 20 patients undergoing a phase I clinical trial with FAA and rhIL-2, and analyzed for nitrate content.
Limitations
The number of patients responding to treatment was small, limiting statistical evaluation.
Participant Demographics
Patients had metastatic malignant melanoma and a performance status < 3 on a 5-grade scale.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website